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Abstract Cyclic nucleotide phosphodiesterases (PDEs) regu-
late physiological processes by degrading intracellular second
messengers, adenosine-3P,5P-cyclic phosphate or guanosine-
3P,5P-cyclic phosphate. The ¢rst crystal structure of PDE4D
catalytic domain and a bound inhibitor, zardaverine, was deter-
mined. Zardaverine binds to a highly conserved pocket that
includes the catalytic metal binding site. Zardaverine ¢lls only
a portion of the active site pocket. More selective PDE4 inhib-
itors including rolipram, cilomilast and ro£umilast have addi-
tional functional groups that can utilize the remaining empty
space for increased binding energy and selectivity. In the crystal
structure, the catalytic domain of PDE4D possesses an exten-
sive dimerization interface containing residues that are highly
conserved in PDE1, 3, 4, 8 and 9. Mutations of R358D or
D322R among these interface residues prohibit dimerization of
the PDE4D catalytic domain in solution.
1 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Changes in intracellular concentration of adenosine-3P,5P-
cyclic phosphate (cAMP) or guanosine-3P,5P-cyclic phosphate
(cGMP) mediate the action of numerous hormones and neu-
rotransmitter signals important for cell growth, di¡erentia-
tion, survival, and in£ammatory processes [1,2]. Phosphodies-
terases (PDEs) are a divergent family of enzymes catalyzing
the hydrolysis of these cyclic nucleotides and therefore pro-
vide the major pathway for eliminating the cyclic nucleotide
signal from cells. Twelve di¡erent mammalian PDE families
have been described, and these can be further divided into
more than 50 subtypes and splice variants.
PDE families share the same general structure. A conserved
region of approximately 380 amino acid residues in carboxy
terminal half of the protein contains a catalytic domain that
consists of 17 K-helices and a short L-hairpin [3]. This region
is conserved between members of the same gene family. A
binuclear metal center crucial for catalysis is located in a
highly conserved pocket surrounded by helices H6, H13,
and the loop between H7 and H8. Binding site of the adenine
ring of the substrate is predicted in the adjacent hydrophobic
pocket. However, the exact structure of substrate or substrate
analog bound to the pocket has not been available yet.
The amino terminal half of PDE sequences contains highly
variable domains that may be involved in enzyme regulation.
Based on sequence homology, the PDE superfamily can be
divided into two groups [1]. The ¢rst group is comprised of
PDE2, 5, 6, 10 and 11. These PDE families contain one or
two GAF domains in their amino terminal regions. PDE5, 6
are highly speci¢c to cGMP and PDE2, 10 and 11 can hydro-
lyze both cAMP and cGMP. The second group includes
PDE1, 3, 4, 7, 8 and 9. PDE families in this group lack
GAF domains. Instead they have variable domains that are
involved in enzyme regulation. In general, the second group of
PDEs favors cAMP over cGMP for a substrate. PDE4, 7 and
8 are highly speci¢c to cAMP and PDE1, 3 and 9 are dual
speci¢c enzymes.
Dialkoxyphenyl containing molecules have been shown to
be selective inhibitors of PDE4 and are being developed as
drugs against asthma and chronic obstructive pulmonary dis-
ease [4,5]. Zardaverine is a representative example of these
inhibitors [6]. Although these drugs have been extensively
studied, detailed structural information about enzyme and
inhibitor interaction remains to be elucidated. In order to
further understand the mechanism of the enzyme reaction
and to facilitate the development of PDE inhibiting drugs,
we undertook structural studies of the PDE4D catalytic do-
main and zardaverine complex.
2. Materials and methods
The minimal catalytic domain of PDE4D (residues 183T to 510S,
GenBank IDU02882) was cloned into a GST fusion expression vector
pGEX4T3 (APbiotech). The fresh transformation mixture was used
directly for large-scale culture without colony puri¢cation. Due to the
toxicity of the PDE gene, even a single round of colony puri¢cation
eliminated soluble expression of the protein. Protein expression was
induced at room temperature using 0.4 mM IPTG. After 12 h of the
induction, the cells were harvested and lysed in a bu¡er containing 50
mM Tris, pH 8.0, 0.4 M NaCl, 5 mM DTT by sonication after 0.2
mg/ml lysozyme treatment on ice. The cell lysate was centrifuged and
the supernatant was loaded on a Q-Sepharose (APbiotech) ion ex-
change column pre-equilibrated with the lysis bu¡er. The £ow-
through fractions were collected and loaded on a glutathione^Sepha-
rose column (APbiotech). The bound protein was eluted with a bu¡er
containing 5 mM glutathione, 50 mM Tris, pH 8.0, 0.4 M NaCl, 5 mM
DTT. The GST^PDE4D fusion protein was cleaved by 0.5% (w/w
protein) thrombin at 4‡C overnight. PDE4D was further puri¢ed by
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Source Q anion exchange and Superdex-200 gel ¢ltration chromatog-
raphy (APbiotech). The puri¢ed protein was concentrated to 70 mg/
ml and used for crystallization. Catalytic activity of the puri¢ed pro-
tein was con¢rmed as previously described [7,8].
PDE4D^zardaverine complex was crystallized using hanging drop
vapor-di¡usion. The concentrated protein solution was mixed with
zardaverine solution at a ¢nal concentration of 3 mM. After 10 min
incubation at 4‡C, the protein^inhibitor complex was crystallized by
mixing 2 Wl protein and 2 Wl crystallization solution containing 0.1 M
sodium cacodylate, pH 6.5, 11% PEG 8000, 0.6 M magnesium acetate,
and 5 mM DTT at room temperature. Protein crystals with a typical
size of 50U50U100 Wm were grown after 1 week. Well isolated single
crystals were separated from large crystal clusters and frozen in a
bu¡er containing 30% ethylene glycol, 0.1 M sodium cacodylate, pH
6.5, 11% PEG 8000, 0.6 M magnesium acetate, and 5 mM DTT using
a stream of boiling liquid nitrogen. A complete data set to 2.9 AR was
collected at the A1 beam line in the Cornell High Energy Synchrotron
Source. The data were indexed with DENZO, and scaled and reduced
with SCALEPACK [9].
The PDE4D^zardaverine structure was solved by molecular re-
placement using the structure of PDE4B catalytic domain as a search
probe. The molecular replacement calculations were performed with
the program AmoRe [10]. The structure was re¢ned using program
CNS [11] with 95% of the data. Five percent of the data was reserved
for the Rfree calculation. Positions of the atoms related by non-crys-
tallographic symmetry (NCS) were tightly restrained throughout the
re¢nement. The R factor dropped from 48% to 27% in a single round
of automatic re¢nement. A strong and continuous electron density
near the metal binding sites was found after 12-fold NCS averaging
(Fig. 1C). Twenty low energy conformations of zardaverine generated
from conformational analysis using a program Cache (Fujitsu) were
¢tted to the density. The best conformation of zardaverine was ob-
vious and selected for the ¢nal re¢nement. The ¢nal model contains
12 PDE4D catalytic domains. Each protein includes one zinc, one
magnesium, one dimethylarsenate (cacodylate), and one zardaverine
molecule.
3. Results and discussion
3.1. Overall structure
The minimal PDE4D catalytic domain [12] was crystal-
lized in the presence of 3 mM zardaverine. The structure of
the protein^inhibitor complex was determined by molecular
replacement using the inhibitor-free PDE4B structure as a
Fig. 1. The structure of zardaverine bound to the PDE4D active site pocket. A: Protein residues are shown in green. Helices are drawn sche-
matically as blue ribbons. The helix-numbering scheme of PDE4D is identical with that of PDE4B [3]. Carbon, nitrogen, oxygen and £uorine
atoms in zardaverine are shown in black, blue, red, and green respectively. Potential hydrogen bonds are drawn in broken red lines. ‘As’ repre-
sents the dimethylarsenate ion. B: Surface representation of the active site pocket. Bound zardaverine is shown using a ball-and-stick model.
The hydrophobic and hydrophilic surfaces of the protein are colored in yellow and green, respectively. Kyte and Doolittle’s hydrophobicity
scale was used for the calculation [22]. The positions of S1, S2, and S3 sub-pockets are indicated by arrows. The residues important for inhibi-
tor binding are written on the surface. P419 is located under F469 and not visible in this orientation. W429 is hidden behind the di£uorome-
thoxy group of zardaverine. C: Twelve-fold NCS averaged 2Fo^Fc electron density map calculated with a model without bound zardaverine.
The re¢ned atomic model of zardaverine is superimposed.
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search probe (Table 1). The PDE4D catalytic domain has 16
K-helices from H1 to H16 and a short L-hairpin. Helices H0
and H17 are not essential for the catalytic activity and were
deleted in the crystallized catalytic domain. The active site
pocket of PDE4D includes both the inhibitor and metal bind-
ing sites. The binuclear metal binding site, important for ca-
talysis, is surrounded by helices H6, H13, and the loop be-
tween H7 and H8. Zardaverine binds to mostly hydrophobic
part of the active site pocket (Fig. 1). Zardaverine binding
induces few structural changes in the protein, except for minor
rearrangements of the side chains. The metal coordination
geometry exhibits few changes and the arsenate ion mimicking
catalytic phosphoryl group is also conserved in the zardaver-
ine bound PDE4D structure.
3.2. Structural comparison of PDE4D and PDE4B catalytic
domains
Amino acid sequences of the catalytic domains of PDE4D
and PDE4B are highly conserved (80% identity) and their
structures can easily be superimposed. Especially residues lo-
cated near the metal and inhibitor binding sites are completely
conserved. Most of the unconserved residues are concentrated
in the helices H2, H3, H5 and intervening loops. However,
even these most divergent regions show only trivial structural
deviations. Furthermore, these regions are located away from
the enzyme active site and thus unlikely play direct roles in the
catalysis.
3.3. Structure of the inhibitor binding pocket
The zardaverine pocket is approximately 12 AR deep and has
an elongated opening 20 AR long by 4.5 AR wide. The shape of
the pocket complements planar and extended PDE inhibitors
and substrates [4]. The upper and lower walls of the binding
pocket are rimmed by hydrophobic residues, F469, L416,
M370, M434, I433, F437, and M454 (Fig. 1A,B). In partic-
ular, the phenolic ring of zardaverine is parallel to F469 with
inter-planar distance of 3.2 AR . F469 is invariant in known
PDE families and the mutation of F469 in PDE4A has enzy-
matic activity and inhibitor binding decreased by more than a
100-fold [12]. Mutations of I433, F437 and M434 also have
greatly reduced inhibitor binding [13]. Potential hydrogen
bonding partners are located in the back and left side of the
pocket. Of these residues, Q466 and Y256 are highly con-
served in PDE families. However, residues N418, P419,
Y426, D264 and T430 of PDE4D have signi¢cant sequence
variations and may provide substrate and inhibitor selectivity
of the enzyme [14]. Zardaverine is a speci¢c inhibitor of PDE3
and PDE4 [6]. Its selectivity is provided, in part, by two hy-
drogen bonds. Ether oxygens of the dialkoxy pharmacophore
make strong hydrogen bonds to the amide nitrogen of the
Q466 side chain. The di£uoromethoxy group of zardaverine
occupies a small sub-pocket surrounded by N418, T430, P419,
Y256, and W429. The structure of the £uorine sub-pocket is
rigid and too small to accept bigger chemical groups. The
substitution of di£uoromethoxyl by bulkier functional groups
signi¢cantly reduces the inhibitors’ binding a⁄nity to the pro-
Table 1
Data collection and re¢nement statistics
Space group P212121
Cell dimensions (AR ) a=97.3, b=164.6, c=325.5
Resolution (AR ) 20.0^2.9
Total re£ections 730 381
Unique re£ections 114 897
Completeness (%) 99.3 (99.2)a
Rmerge (%)b 7.3 (36.7)a
Resolution (AR ) 20.0^2.9
Number of protein molecules in
asymmetric unit
12
Re£ections 114 897
Rfree (%)c (MFMs 0 c) 27.1
Rcryst (%)c (MFMs 0 c) 22.9
Average B-value
Protein 46.4
Ligand 56.1
R.m.s deviations from ideality
Bonds (AR ) 0.008
Angles (‡) 1.26
Improper angles (‡) 0.82
aStatistics of the highest resolution shell are shown in parentheses.
bRmerge =ghklgjMIj(hkl)3GI(hkl)fM/ghklgjMIj(hkl)M, where Ij(hkl) and
GI(hkl)f are the intensity of measurement j and the mean intensity
for the re£ection with indices hkl, respectively.
cRcryst;free =ghklNFcalc(hkl)M-MFobs(hkl) N/ghklMFobsM, where the crystal-
lographic and free R-factors are calculated, including and excluding
re¢ned re£ections, respectively. The free re£ections constituted 5%
of the total number of re£ections.
Fig. 2. Dialkoxyphenyl containing PDE4 inhibitors [4,6,15,16,23^
25]. IC50 values are written in parentheses. The dialkoxy pharmaco-
phores are colored in red.
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tein [15]. Interestingly, the £uorine sub-pocket has two poten-
tial hydrogen bond acceptors, N418 ON and T430 OQ. There-
fore, replacing hydrogen accepting £uorine atoms with hydro-
gen donating groups may greatly improve the inhibitor’s
potency and selectivity. Two nitrogen atoms in the pyridazi-
none ring are situated at a distance that is ideal for hydrogen
bonding from the arsenate binding site [3]. In physiological
conditions, the arsenate site is probably occupied by phos-
phate ions. Most of the PDE4 selective inhibitors contain
hydrogen donors or acceptors at similar positions that may
interact with the arsenate oxygens (Fig. 2) [4].
Zardaverine ¢lls approximately half of the active site pock-
et. Recently developed and more selective PDE4 inhibitors are
likely to utilize empty sub-pockets for additional binding en-
ergy and selectivity [4]. For clarity of description, we call these
sub-pockets S1, S2, and S3 (Fig. 1B). Structural comparison
of dialkoxy containing PDE inhibitors is relatively straightfor-
ward, due to the elongated planar shape of the molecule and
common dialkoxy pharmacophore (Fig. 2). The S1 sub-pock-
et, formed by M434, M454, and F437, is a shallow groove
rather than a deep pocket. In the inhibitors more speci¢c than
zardaverine, the methoxy group of dialkoxy pharmacophore
is replaced by bulkier groups that may pack against the S1
surface. Rolipram and cilomilast have cyclopentyl groups
while ro£umilast contains a cyclopropyl group. The 7-me-
thoxybenzofuran derivative (compound 5, Fig. 2) has an ace-
tylfuran ring replacing the methoxy group of the dialkoxy
pharmacophore in zardaverine.
The S2 sub-pocket consists of side chains of M370, S371,
E327, N306, D369, metal ions and the arsenate ion (Fig. 1B).
Speci¢c PDE4 inhibitors tend to have more elongated struc-
tures than zardaverine, capable of ¢lling the S2 sub-pocket.
Ro£umilast has an additional amide group and the inhibitor
L-791,943 has two extra carbons in its chemical backbone.
The extended chemical chains may interact more e⁄cient-
ly with the hydrophobic wall made of M370, explaining
the higher a⁄nity and selectivity of these inhibitors. Even
these selective compounds do not completely ¢ll the S2 sub-
pocket of PDE4D. Su⁄cient space remains for a few more
carbon chains. If additional carbon chains and hydrogen-
bonding partners could be designed in the S2 sub-pocket,
then the potency and selectivity of the compound might be
improved.
The S3 sub-pocket branches approximately 90‡ from the
middle of the main active site pocket. Residues F437, E436,
Q440, S305, C455, and S452 line the wall of the S3 sub-pock-
et. The additional aromatic rings of L-791,943 and the indan-
1,3-dione derivative (compound 7, Fig. 2) could occupy the S3
pocket and make hydrophobic and hydrogen bonding inter-
actions with the protein side chains. A previous modeling
study with L-791,943 and the indan-1,3-dione derivative dem-
onstrated that the additional aromatic rings branch perpen-
Fig. 3. The structure and conservation of the dimerization interface. A: The two subunits of PDE dimer are shown in red and blue. The posi-
tion of a non-crystallographic two-fold axis is marked by a ¢lled ellipsoid. Important interface residues are drawn. Potential hydrogen bonds
are shown in broken red lines. B: Sequence alignment of interface residues. Representative members of each PDE family are aligned. Con-
served interface residues are shown in red. C: Surface representation of PDE4D catalytic domain. Surface area conserved more than 80% is
colored in green. Amino acid sequences of PDE1, 3, 4, 8 and 9 were aligned for calculation of conservation.
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dicularly from the main ring systems [16]. The shapes of these
molecules match well with the T-shaped PDE active site pock-
et. The S1, S2, and S3 sub-pockets are highly conserved over-
all, but they have variable patches. M434 and M454 of S1,
M370 of S2 and S305, C455 and S452 of the S3 sub-pocket
have signi¢cant sequence variations in known PDE families.
These variable patches may provide good targets for the de-
sign of selective PDE inhibitors.
3.4. Arsenate binding site
The structure of zardaverine bound PDE4D exhibits a met-
al coordination geometry practically identical to that of ligand
free PDE4B (Fig. 1A) [3]. The permanent metal ion, presum-
ably zinc, is coordinated by H261, H297, D298, D415, and a
bridging hydroxide ion. The variable metal ion that is likely to
be magnesium from the crystallization bu¡er is coordinated
by D298, the shared bridging hydroxide, and four water mol-
ecules. In PDE4B structure, Xu et al. found an arsenate bind-
ing site located 2.6 AR from the site of the metal center. This
arsenate site is also conserved in the zardaverine bound
PDE4D structure. In our zardaverine bound PDE4 structure,
the arsenate site is occupied by dimethyl arsenate (cacodylate)
from the crystallization bu¡er. The observation that both
PDE4B and PDE4D, crystallized in very di¡erent conditions,
contain anion binding sites at the same positions strongly
supports the hypothesis that the arsenate may mimic the
phosphoryl ester in cyclic nucleotide substrates. Furthermore,
the position and geometry of the PDE arsenate site is similar
to those of the substrate mimicking tungstate site in protein
phosphatase I [17]. Protein phosphatase I also contains a bi-
nuclear metal center in the active site and has a reaction
mechanism similar to that of PDE.
3.5. Dimerization of PDE
PDE4D^zardaverine complex forms a dodecamer in the
asymmetric unit of the crystal. Dimers of PDE trimerize to
form a hexameric unit. The two hexameric units stack in a
tail-to-tail manner and become a dodecameric complex in the
crystal. Trimeric and hexameric interfaces are unlikely to have
biological signi¢cance because their contact areas are limited
and the mediating residues are highly variable in known PDE
sequences. On the other hand, the dimeric interface could
represent a physiological dimer interface (Fig. 3A). Both full
length and the catalytic domain of PDE4 multimerize in so-
lution (Fig. 4) [18]. To verify that this crystallographic dimer
interface is part of the multimerization interface in solution,
either R358D or D322R mutation was introduced to the
PDE4D catalytic domain. These residues were chosen because
they do not have structural roles other than dimerization. The
electrical charge of the residues was reversed to disrupt dimer
interactions e⁄ciently. The oligomeric state of the puri¢ed
mutants was probed by glutaraldehyde-mediated cross-linking
(Fig. 4B). In the condition where the wild type protein was
cross-linked as a dimer, neither of the mutant proteins was
cross-linked. Furthermore, the puri¢ed R358D mutant protein
was eluted later than wild type protein in gel ¢ltration chro-
matography, which is consistent with the monomeric state of
the mutant and dimeric state of the wild type protein (Fig.
4A). These data con¢rm that the crystallographic dimer inter-
face indeed mediates protein dimerization in solution. Resi-
dues involved in the dimerization, E315, N321, D322, N328,
R358, and I362, are highly conserved in PDE1, 3, 4, 8, and 9
but not in PDE2, 5, 6, 7, 10, and 11 (Fig. 3B). Consistent with
the sequence homology data, the catalytic domain of PDE5
has been shown to be a monomer in solution [19]. Interest-
Fig. 4. The dimerization of wild type and mutant PDE4D catalytic domain. A: Puri¢ed wild type and R358D mutant protein were injected
into a Superdex 200 (APbiotech) gel ¢ltration column. Elution volumes for molecular weight standards are indicated. B: Glutaraldehyde-medi-
ated cross-linking of the puri¢ed wild type and mutant proteins was performed as published [26]. The cross-linked proteins were separated by
SDS^PAGE and stained with Coomassie brilliant blue R-250. Glutaraldehyde concentrations used for each lanes are, 1, 6, 11: 0%; 2, 7, 12:
0.01%; 3, 8, 13: 0.03%; 4, 9, 14: 0.1%; 5, 10, 15: 0.3%. Mutant catalytic domains of PDE4D were cloned into the pAcHLTA vector (BD
Pharmingen) and expressed using a baculovirus expression system. Mutant proteins could not be overexpressed in Escherichia coli. They run in
as slightly higher molecular weight due to hexa-histidine tags. In control experiments with wild type protein expressed in insect cells, the histi-
dine tag did not a¡ect cross-linking results (data not shown).
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ingly, PDE2, 5, 6, 10 and 11 are closely related to each other
in evolution and contain GAF domains in their amino termi-
nal region [1,2,20,21]. PDE7 is the only exception. Although
PDE7 does not contain GAF domains, its amino acid sequen-
ces are closely related to the GAF containing PDEs in the
phylogenetic tree [1,21]. In the PDE4 catalytic domain, the
dimer interface is the most conserved surface besides the ac-
tive site pocket (Fig. 3C). High sequence conservation of the
interface residues in PDE1, 3, 4, 8, and 9 suggests that dimer-
ization mediates indispensable biological functions for these
types of PDEs including PDE4D.
3.6. Conclusions and implications
This is the ¢rst structure of PDE^inhibitor or PDE^sub-
strate analog complex. Majority of PDE4 speci¢c inhibitors
under development contain dialkoxyphenyl pharmacophore
[4]. Our zardaverine^PDE4D structure shows how these in-
hibitors interact with the enzyme. It also provides clues about
PDE and substrate interactions and illustrates the structure of
the evolutionary conserved dimerization interface. This struc-
ture will be used as a template for the design of novel PDE
inhibiting drugs.
Acknowledgements: We thank the sta¡ of the Cornell High Energy
Synchrotron Source (MacChess) for help with data collection. This
study was supported by a grant of the Korea Health 21 RpD Project,
Ministry of Health and Welfare, Republic of Korea (01-PJ1-PG3-
20900-0029) and funds from University of Maryland Baltimore
County. J.M. is supported by the MD/PhD program of the University
of Maryland School of Medicine. Part of the research was done while
J.-O.L and H.L. were in University of Maryland at Baltimore County.
References
[1] Francis, S.H., Turko, I.V. and Corbin, J.D. (2001) Prog. Nucleic
Acid Res. Mol. Biol. 65, 1^52.
[2] Houslay, M.D. (2001) Prog. Nucleic Acid Res. Mol. Biol. 69,
249^315.
[3] Xu, R.X. et al. (2000) Science 288, 1822^1825.
[4] Huang, Z., Ducharme, Y., Macdonald, D. and Robichaud, A.
(2001) Curr. Opin. Chem. Biol. 5, 432^438.
[5] Torphy, T.J. and Page, C. (2000) Trends Pharmacol. Sci. 21,
157^159.
[6] Schudt, C., Winder, S., Muller, B. and Ukena, D. (1991) Bio-
chem. Pharmacol. 42, 153^162.
[7] Ball, E.H., Narindrasorasak, S. and Sanwal, B.D. (1979) Can.
J. Biochem. 57, 1220^1228.
[8] Laiberte, F. et al. (2000) Biochemistry 39, 6449^6458.
[9] Otwinowski, Z. and Minor, W. (1997) Methods Enzymol. 276,
461^472.
[10] Navaza, J. (1994) Acta Crytallogr. A50, 157^163.
[11] Brunger, A.T. et al. (1998) Acta Cryst. D54, 905^921.
[12] Richter, W., Unciuleac, L., Hermsdorf, T., Kronbach, T. and
Dettmer, D. (2001) Cell Signal. 13, 287^297.
[13] Atienza, J.M., Susanto, D., Huang, C., McCarty, A.S. and Co-
licelli, J. (1999) J. Biol. Chem. 274, 4839^4847.
[14] Herman, S.B., Juilfs, D.M., Fauman, E.B., Juneau, P. and Me-
netski, P. (2000) Mol. Pharmacol. 57, 991^999.
[15] Marivet, M.C. et al. (1989) J. Med. Chem. 32, 1450^1457.
[16] He, W. et al. (1998) J. Med. Chem. 41, 4216^4223.
[17] Eglo¡, M.P., Cohen, P.T., Reinemer, P. and Barford, D. (1995)
J. Mol. Biol. 254, 942^959.
[18] Conti, M. et al. (1995) Biochemistry 34, 7979^7987.
[19] Fink, T.L., Francis, S.H., Beasley, A., Grimes, K.A. and Corbin,
J.D. (1999) J. Biol. Chem. 274, 34613^34620.
[20] Fawcett, L. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 3702^
3707.
[21] Koyanagi, M. et al. (1998) FEBS Lett. 436, 323^328.
[22] Kyte, J. and Doolittle, R.F. (1982) J. Mol. Biol. 157, 105^132.
[23] Christensen, S.B. et al. (1998) J. Med. Chem. 41, 821^835.
[24] Ashton, M.J. et al. (1994) J. Med. Chem. 37, 1696^1703.
[25] McGarry, D.G. et al. (1999) Bioorg. Med. Chem. 7, 1131^1139.
[26] Pavletich, N.P., Chambers, K.A. and Pabo, C.O. (1993) Genes
Dev. 7, 2556^2564.
FEBS 26582 9-10-02 Cyaan Magenta Geel Zwart
M.E. Lee et al./FEBS Letters 530 (2002) 53^5858
